beLAB1407

beLAB1407 is a £20 million ($27 million) translational research collaboration launched in 2021 to identify and advance novel drug discovery projects from leading UK academic institutions. The initiative brings together Evotec SE and Bristol Myers Squibb with the Universities of Birmingham, Dundee, Edinburgh, and Nottingham. It leverages Evotec’s integrated drug discovery and development platform alongside Bristol Myers Squibb's therapeutic expertise to bridge the gap between academic innovation and commercial drug development. The collaboration focuses on a broad range of therapeutic areas, including oncology, neuroscience, and immunology, aiming to accelerate the translation of basic research into high-quality drug candidates. By providing academic researchers with industrial-scale resources, beLAB1407 seeks to foster a more efficient path toward clinical validation and therapeutic breakthroughs.